drugset / Trial / NCT00373256

A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer

NCT00373256

Phase 3 Completed 488 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare treatment with SU011248 plus paclitaxel versus bevacizumab plus paclitaxel to determine which treatment works better against breast cancer

Timeline

Start
2006-11
Primary completion
2009-06
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bevacizumab Monoclonal antibody 10 mg/kg Intravenous
Subject Sunitinib Small molecule 37.5 mg Oral
Comparator Paclitaxel Small molecule 90 mg/m2 Intravenous

Indications